Non-alcoholic fatty liver disease was not something I talked about much before surgery. It felt like one of those conditions that sits quietly in the background, managed with annual blood tests and vague advice about diet and exercise, while the bigger picture of what it might become stays carefully unspoken between you and your GP. By the time we started seriously considering gastric sleeve surgery in early 2024, my liver disease had progressed to stage 2 and was heading towards stage 3. It was the primary reason I had the operation.
Within three weeks of my gastric sleeve in March 2024, my liver function had returned to normal. Three weeks. After more than a decade of living with NAFLD and watching it worsen despite my efforts, the change was almost incomprehensible. This article is about that experience, about what NAFLD is, why it is so closely linked to obesity, and what the evidence says about weight loss surgery as a treatment pathway.
What Is Non-Alcoholic Fatty Liver Disease?
Non-alcoholic fatty liver disease is a condition in which excess fat accumulates in the liver cells of people who drink little or no alcohol. It is now one of the most common liver conditions in the UK, affecting an estimated one in three adults to some degree. The condition exists on a spectrum. Simple steatosis, where fat is present in the liver but without significant inflammation, is at the mild end. Non-alcoholic steatohepatitis (NASH), where fat accumulation is accompanied by inflammation and liver cell damage, is more serious. If NASH progresses, it can lead to fibrosis, cirrhosis, and ultimately liver failure.
The condition is strongly associated with obesity, type 2 diabetes, high blood pressure, and metabolic syndrome. Visceral fat, the fat stored around the organs rather than under the skin, is particularly implicated. The liver receives blood directly from the portal vein, which drains the intestines and surrounding adipose tissue, so excess visceral fat exposes the liver to a constant stream of fatty acids and inflammatory signals that promote disease progression.
I had been living with NAFLD for over ten years. At the point we started exploring surgical options, my liver was at stage 2 fibrosis. The trajectory, without significant intervention, was towards stage 3, and eventually cirrhosis. That reality sat heavily with me in a way that other comorbidities, the high blood pressure, the pre-diabetic markers, did not quite match. The liver does not have good treatment options once significant fibrosis sets in.
Why Weight Loss Is the Primary Treatment
There is currently no approved medication that treats NAFLD or NASH directly, though several are in late-stage clinical trials. The evidence-based treatment for the majority of patients is sustained weight loss, typically a reduction of at least 7 to 10 percent of body weight to see meaningful improvement in liver inflammation, and greater reductions to see regression of fibrosis.
That threshold is exactly where the difficulty lies. For someone carrying the amount of weight I was carrying, achieving and sustaining a 10 percent reduction through diet and exercise alone had proven extremely difficult over the years I had tried. The metabolic and hormonal changes associated with significant obesity work against sustained weight loss in ways that go beyond willpower or effort. This is not an excuse; it is the clinical reality that led to bariatric surgery becoming a recognised treatment pathway for NAFLD in guidelines from the British Society of Gastroenterology and other bodies.
What the Research Shows
The evidence for bariatric surgery in NAFLD is among the most compelling in the entire field of obesity medicine. Multiple large studies have demonstrated that significant weight loss following bariatric surgery leads to substantial improvements in liver histology, meaning the actual physical appearance of liver tissue under a microscope. Studies consistently show reductions in liver fat content, inflammation, and in many cases regression of fibrosis, including in patients with established fibrosis at the time of surgery.
The speed of improvement is part of what makes the bariatric surgery pathway so striking in NAFLD specifically. Changes in liver fat can begin within days to weeks of surgery, driven initially by the caloric restriction rather than by the weight loss itself. This early metabolic effect, independent of the weight actually lost, is thought to explain why improvement can occur so quickly. It is almost certainly the mechanism behind the recovery I experienced in those first three weeks.
Long-term follow-up data is also encouraging. Studies tracking NAFLD patients for five to ten years following bariatric surgery show sustained improvements in liver health in the majority of cases, provided weight regain is avoided. For patients with established fibrosis, surgery does not guarantee reversal, but the probability of stabilisation or improvement is substantially better than with conservative management alone.
My Experience: Three Weeks That Changed Everything
I had liver function tests done as part of the standard post-operative monitoring in the weeks following surgery. When the results came back at three weeks showing liver enzymes within the normal range for the first time in years, I sat with that for a while before I could quite process it. I had spent over a decade watching those numbers creep in the wrong direction despite every intervention my GP and I had tried. To see them normalise so quickly was genuinely one of the most significant moments of the entire surgical experience.
I want to be careful about how I frame this, because my experience is not a guarantee of anyone else’s outcome. NAFLD progresses at different rates in different people. The degree of fibrosis at the time of surgery, the presence of other conditions, and post-operative weight loss trajectory all affect what happens to the liver. My liver function normalising at three weeks does not mean everyone with NAFLD who has bariatric surgery will see the same result, or on the same timeline.
What it does mean is that the surgery created the conditions for my liver to begin recovering from something I had been managing for over a decade. Two years on, my liver function remains normal. That is not something I take for granted.
NAFLD and Surgical Risk
It is worth addressing directly whether having NAFLD, particularly with established fibrosis, affects the risk of bariatric surgery. The answer is: it depends on the stage of liver disease.
In simple steatosis and early NASH without significant fibrosis, the surgical risk is not substantially elevated and most bariatric teams operate without specific liver-related concerns. In patients with stage 2 or 3 fibrosis, as I had, the surgical team needs to be aware and may want pre-operative input from a hepatologist. In patients with established cirrhosis, particularly decompensated cirrhosis, bariatric surgery carries much higher risk and may not be appropriate. This is a discussion to have explicitly with your surgeon and, if you have established fibrosis, with a liver specialist as well.
The Weight Loss Riga team were aware of my liver disease and its stage before my operation. It was part of the pre-operative assessment, and the decision to proceed was made with that knowledge. The surgery itself was uneventful and the liver disease did not complicate the procedure or recovery in the way that might be assumed.
Post-Operative Monitoring If You Have NAFLD
If you have NAFLD and are having or have had bariatric surgery, regular liver function monitoring post-operatively is important. Ask your GP to include liver enzymes in your routine annual blood tests and, if you have established fibrosis, discuss whether follow-up liver imaging or a fibroscan is appropriate at one or two years post-op. The goal is to document the improvement and catch any unexpected changes early.
Weight regain is the primary risk factor for NAFLD recurrence or progression after surgery. Maintaining your weight loss through the lifestyle and nutritional habits established post-operatively is the long-term strategy for keeping your liver healthy.
Sources
NHS. Non-alcoholic fatty liver disease (NAFLD). Available at: https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/
NICE. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline NG49. Available at: https://www.nice.org.uk/guidance/ng49
British Society of Gastroenterology. Guidelines on the management of abnormal liver blood tests. Available at: https://www.bsg.org.uk/
BOMSS. Guidelines on peri-operative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery. Available at: https://www.bomss.org.uk/
About this content
This blog is written by James and Kirsten, a couple from the UK who had gastric sleeve surgery together in March 2024.
We started this blog because we couldn't find any sources of content that details before surgery, the surgery and then life post surgery - so we decided to write one ourselves.
Everything on this site is based on our own experience and the research we have done along the way. It is not medical advice. Gastric sleeve surgery is a serious procedure and every patient's journey is different. Please always consult your own bariatric team or GP before making any decisions about your health or treatment.
Some posts on this site may contain featured or sponsored content, or affiliate links. Where this is the case, it will always be clearly stated at the top of the article. Our opinions are always our own.
Publish Date: 6 June 2026 | Last Reviewed: 6 June 2026 | Next Planned Review: 6 December 2027